[go: up one dir, main page]

MX2020011562A - Agonistas del receptor de la hormona tiroidea y usos de los mismos. - Google Patents

Agonistas del receptor de la hormona tiroidea y usos de los mismos.

Info

Publication number
MX2020011562A
MX2020011562A MX2020011562A MX2020011562A MX2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A
Authority
MX
Mexico
Prior art keywords
hormone receptor
thyroid hormone
receptor agonists
methods
compositions
Prior art date
Application number
MX2020011562A
Other languages
English (en)
Inventor
Gene Hung
Bohan Jin
Qing Dong
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of MX2020011562A publication Critical patent/MX2020011562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos y composiciones para el tratamiento de afecciones, enfermedades o trastornos asociados con la actividad del receptor de la hormona tiroidea. Los métodos y composiciones descritos en la presente incluyen el uso de al menos un agonista del receptor de la hormona tiroidea.
MX2020011562A 2018-06-12 2019-05-28 Agonistas del receptor de la hormona tiroidea y usos de los mismos. MX2020011562A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862684113P 2018-06-12 2018-06-12
US201862731364P 2018-09-14 2018-09-14
US201862767402P 2018-11-14 2018-11-14
PCT/US2019/034199 WO2019240938A1 (en) 2018-06-12 2019-05-28 Thyroid hormone receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2020011562A true MX2020011562A (es) 2021-02-02

Family

ID=68842670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011562A MX2020011562A (es) 2018-06-12 2019-05-28 Agonistas del receptor de la hormona tiroidea y usos de los mismos.

Country Status (12)

Country Link
US (2) US11964964B2 (es)
EP (2) EP3807267B1 (es)
JP (1) JP7181386B2 (es)
KR (1) KR102531771B1 (es)
CN (2) CN113683597A (es)
AU (1) AU2019287679B2 (es)
BR (1) BR112020022146A2 (es)
CA (1) CA3099752C (es)
ES (1) ES3029158T3 (es)
MX (1) MX2020011562A (es)
PT (1) PT3807267T (es)
WO (1) WO2019240938A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689853B1 (en) 2012-09-17 2021-11-24 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN111646979B (zh) * 2018-01-23 2021-08-31 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
PT3807267T (pt) 2018-06-12 2025-05-22 Xizang Haisco Pharmaceutical Co Ltd Agonistas do recetor da hormona da tiroide e usos dos mesmos
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
TWI840423B (zh) 2018-10-12 2024-05-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN119552152A (zh) * 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111592528A (zh) * 2019-02-20 2020-08-28 苏州泽璟生物制药股份有限公司 氘代的哒嗪酮及其衍生物和药物组合物
WO2020169069A1 (en) 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
TW202108556A (zh) * 2019-05-10 2021-03-01 大陸商深圳微芯生物科技股份有限公司 一種噠嗪酮衍生物及其應用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202115029A (zh) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
CN112409340B (zh) * 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
WO2021057791A1 (zh) * 2019-09-24 2021-04-01 广东东阳光药业有限公司 一种作为甲状腺激素Beta受体激动剂的化合物及其用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
CN113454069B (zh) * 2019-11-26 2025-03-14 昆药集团股份有限公司 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
CN113045551B (zh) * 2019-12-27 2024-07-09 广东东阳光药业股份有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
JP2023510835A (ja) 2020-01-13 2023-03-15 エコジーン （シャンハイ） カンパニー リミテッド 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン
CN115811972A (zh) * 2020-05-13 2023-03-17 拓臻制药公司 肝脏病症的组合治疗
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
US20240025875A1 (en) * 2020-09-17 2024-01-25 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
WO2022068915A1 (zh) * 2020-09-30 2022-04-07 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
KR20230117564A (ko) 2020-10-23 2023-08-08 마드리갈 파마슈티칼스, 인크. 갑상선 호르몬 유사체의 중간체로서 6-(4-니트로-페녹시)-2h-피리다진-3-온 및 6-(4-아미노-페녹시)-2h-피리다진-3-온 유도체의 제조 공정
KR20230123929A (ko) 2020-11-06 2023-08-24 알리고스 테라퓨틱스 인코포레이티드 갑상선 수용체 작용제로서의 피리다지논 유도체 및 이의 용도
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
CN116723844A (zh) 2020-11-06 2023-09-08 阿利戈斯治疗公司 作为甲状腺激素受体β (TR-β)激动剂的双环哒嗪酮
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
KR20240018414A (ko) * 2021-03-04 2024-02-13 후캉 (상하이) 헬스 테크놀로지 씨오 엘티디 방향족 화합물, 그 제조 방법 및 적용
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
CN114409524A (zh) * 2021-12-31 2022-04-29 上海柏狮生物科技有限公司 一种2,6-二氯苯乙酸的制备方法
US20250115559A1 (en) * 2022-02-07 2025-04-10 Xizang Haisco Pharmaceutical Co., Ltd. Preparation method of pyridazinone derivative, and intermediate thereof
KR20240146054A (ko) * 2022-02-07 2024-10-07 시젱 하이스코 파마수티칼 씨오., 엘티디. 갑상선 호르몬 수용체 작용제로서의 다결정체 및 이의 용도
CN119137113A (zh) * 2022-02-10 2024-12-13 马德里加尔制药公司 THRβ类似物及其用途
CN118146217A (zh) 2022-12-07 2024-06-07 昆药集团股份有限公司 一种甲状腺激素β受体激动剂、晶型、制备方法和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
TW202440528A (zh) * 2023-03-28 2024-10-16 大陸商西藏海思科製藥有限公司 選擇性THRβ激動劑關鍵中間體的合成方法
TW202506131A (zh) * 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法
CN116768802A (zh) * 2023-05-25 2023-09-19 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
WO2025036142A1 (zh) * 2023-08-16 2025-02-20 西安新通药物研究股份有限公司 一种哒嗪酮化合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1088819T3 (da) * 1999-09-30 2005-09-12 Pfizer Prod Inc 6-azauracilderivater som thyroidreceptorligander
WO2003064369A1 (fr) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
AU2006271721C1 (en) * 2005-07-21 2013-09-19 F. Hoffmann-La Roche Ag Pyridazinone derivatives as thyroid hormone receptor agonists
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
EP3689853B1 (en) 2012-09-17 2021-11-24 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN115154467B (zh) * 2016-06-03 2024-08-23 坎莫森特里克斯公司 治疗肝纤维化的方法
KR20190109387A (ko) 2016-10-18 2019-09-25 마드리갈 파마슈티칼스, 인크. Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
CN111646979B (zh) 2018-01-23 2021-08-31 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
PT3807267T (pt) 2018-06-12 2025-05-22 Xizang Haisco Pharmaceutical Co Ltd Agonistas do recetor da hormona da tiroide e usos dos mesmos
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP4574208A2 (en) 2025-06-25
US20240360106A1 (en) 2024-10-31
US20210115022A1 (en) 2021-04-22
EP3807267B1 (en) 2025-03-19
JP7181386B2 (ja) 2022-11-30
EP3807267A1 (en) 2021-04-21
ES3029158T3 (en) 2025-06-23
US12358899B2 (en) 2025-07-15
AU2019287679B2 (en) 2022-04-21
WO2019240938A1 (en) 2019-12-19
US11964964B2 (en) 2024-04-23
CA3099752A1 (en) 2019-12-19
JP2021531325A (ja) 2021-11-18
CA3099752C (en) 2023-12-19
AU2019287679A1 (en) 2020-11-26
KR102531771B1 (ko) 2023-05-11
EP3807267A4 (en) 2022-03-16
CN113683597A (zh) 2021-11-23
PT3807267T (pt) 2025-05-22
KR20200143711A (ko) 2020-12-24
BR112020022146A2 (pt) 2021-01-26
CN111801324A (zh) 2020-10-20
CN111801324B (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MY194619A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12020550779A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ751746A (en) Combination therapy with controlled-release cnp agonists
WO2018067520A3 (en) Therapeutic agents and methods:
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2019003889A (es) Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
MX2019003021A (es) Combinacion de agonistas de fxr.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
IL280990A (en) Use of alpha-2 adrenergic receptor agonists to improve vision
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
WO2018140799A3 (en) Neurotrophin mutants and use thereof for treating neurodegenerative diseases and disorders
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.